SCHEMBL20137041

SCHEMBL20137041

CC(C)(C)OC(=O)CCCOc1cc(C(F)(F)F)ccc1C=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.38
NR1H2 P55055 3/20 0.38
MGLL Q99685 2/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
CYP2C19 P33261 2/20 0.38
USP2 O75604 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PPARA Q07869 3/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
HTT P42858 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
ALOX5 P09917 2/20 0.37
PTGES O14684 1/20 0.37
NR1H3 Q13133 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20151840 0.84 TSHR (0.48) KDM4EALDH1A1HPGDPPARAPPARG
SCHEMBL20166345 0.84 MGLL (0.47) MGLLKDM4EALDH1A1HPGDCYP2C19
SCHEMBL20168837 0.83 MAPT (0.49) KDM4EALDH1A1HPGDCYP2C19MAPT
SCHEMBL25470720 0.83 PTGDR2 (0.45) KDM4EALDH1A1HPGDCYP2C19HTT
SCHEMBL21822736 0.80 PTGDR2 (0.43) RXRAMGLLKDM4EALDH1A1HPGD
SCHEMBL953869 0.79 PTGDR2 (0.48) ALDH1A1HPGDHSD17B10PPARAPPARG
SCHEMBL23087373 0.79 PTGDR2 (0.43) KDM4EALDH1A1HPGDCYP2C19KMT2A
SCHEMBL25470728 0.79 PTGDR2 (0.43) KDM4EALDH1A1HPGDCYP2C19KMT2A
SCHEMBL23087387 0.79 PTGDR2 (0.43) KDM4EALDH1A1HPGDCYP2C19KMT2A
SCHEMBL22090766 0.78 KDM4E (0.45) KDM4EALDH1A1HPGDCYP2C19USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541820-B1 MAGL INHIBITORS H LUNDBECK AS (DK) 2023-07-05 EP disclosed
EP-3541820-B1 MAGL INHIBITORS H LUNDBECK AS (DK) 2023-07-05 EP disclosed
US-11691975-B2 MAGL inhibitors H. LUNDBECKA/S (DK) 2023-07-04 US disclosed
US-11691975-B2 MAGL inhibitors H. LUNDBECKA/S (DK) 2023-07-04 US disclosed
US-20220135563-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2022-05-05 US disclosed
US-20220135563-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2022-05-05 US disclosed
CN-110267962-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 CN disclosed
CN-110267963-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 CN disclosed
US-11059822-B2 MAGL inhibitors H. LUNDBECK A/S (DK) 2021-07-13 US disclosed
US-11059822-B2 MAGL inhibitors H. LUNDBECK A/S (DK) 2021-07-13 US disclosed
US-20200291023-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2020-09-17 US disclosed
EP-3541820-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 EP disclosed
EP-3541821-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 EP disclosed
US-10093635-B2 MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2018-10-09 US disclosed
WO-2018093949-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093949-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134674-A1 MAGL INHIBITORS MAG, MAGI3, MGLL RXRA 3591/4885NR1H2 1693/4885MGLL 3/4885
US-11059822-B2 MAGL inhibitors MAG, MAGI3, MGLL RXRA 2778/4885NR1H2 472/4885MGLL 3/4885
US-20220135563-A1 MAGL INHIBITORS MAG, MAGI3, MGLL RXRA 2778/4885NR1H2 472/4885MGLL 3/4885
US-20200291023-A1 MAGL INHIBITORS MAG, MAGI3, MGLL RXRA 2778/4885NR1H2 472/4885MGLL 3/4885
US-11691975-B2 MAGL inhibitors MAG, MAGI3, MGLL RXRA 2778/4885NR1H2 472/4885MGLL 3/4885
US-10093635-B2 MAGL inhibitors MAG, MAGI3, MGLL RXRA 3591/4885NR1H2 1693/4885MGLL 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.